Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers

British Journal of Clinical Pharmacology

Volumn 72, Issue 2, 2011, Pages 226-234

  Malhotra, Bimal ^a   Darsey, Edress ^b   Crownover, Penelope ^a   Fang, Juanzhi ^a   Glue, Paul ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Fesoterodine; Overactive bladder; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; FESOTERODINE; TOLTERODINE;

ABDOMINAL PAIN; ADULT; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEADACHE; HEART INFARCTION; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; BIOLOGICAL AVAILABILITY; CRESOLS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE;

EID: 79960161668     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03948.x     Document Type: Article

References (21)

1. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94.
2. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
3. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11: 13-27.
4. Tubaro A, De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update Series 2004; 2: 161-9.
5. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future 2004; 29: 715-20.
6. Zanger U, Raimundo S, Eichelbaum S. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37.
7. Toviaz (fesoterodine). Full Prescribing Information. New York: Pfizer Inc., 2008.
8. Bock D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenet Genomics 1994; 4: 209-18.
9. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6-13.
10. Detrol LA® (tolterodine tartrate). Full Prescribing Information. Kalamazoo, MI: Pharmacia & Upjohn Company, 2005.
11. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001; 40: 227-35.
12. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50.
13. Malhotra B, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008; 46: 556-63.
14. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5- hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009; 16: 481-9.
15. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin Pharmacol Ther 1998; 63: 529-39.
16. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 1787-96.
17. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-9.
18. Nilvebrant L. Clinical experiences with tolterodine. Life Sci 2001; 68: 2549-56.
19. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.
20. Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010; 105: 58-66.
21. Kaplan S, Schneider T, Foote J, Guan Z, Carlsson M, Gong J, on behalf of the 2nd Fesoterodine Assessment and Comparison Versus Tolterodine (FACT 2) Study Group. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2010; doi: 10.1111/j.1464-410X.2010.09640.x. (Epub ahead of print).